Share Price and Basic Stock Data
Last Updated: October 18, 2025, 6:46 pm
| PEG Ratio | 9.54 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Sumitomo Chemical India Ltd operates within the agrochemicals and pesticides sector, reporting a market capitalization of ₹26,342 Cr. The company’s revenue from operations stood at ₹3,511 Cr for the fiscal year ending March 2023, reflecting a robust growth trajectory compared to ₹3,060 Cr in March 2022. Despite a decline to ₹2,833 Cr in March 2024, the trailing twelve months (TTM) revenue rebounded to ₹3,307 Cr, showcasing the company’s resilience. Quarterly sales figures indicate fluctuations, with a peak of ₹1,122 Cr in September 2022 and a low of ₹652 Cr in March 2023. The operating profit margin (OPM) was reported at 19% for March 2023, slightly lower than the 20% recorded in March 2022. This suggests that while revenue growth has been substantial over the long term, the recent fiscal year experienced challenges that impacted profitability. The steady increase in sales, alongside a solid revenue base, positions Sumitomo Chemical India as a significant player in the industry, albeit with the need for improved consistency in financial performance.
Profitability and Efficiency Metrics
In terms of profitability, Sumitomo Chemical India reported a net profit of ₹503 Cr for the fiscal year ending March 2023, which represents a growth from ₹434 Cr in March 2022. However, the net profit saw a decline to ₹370 Cr in March 2024, highlighting potential operational challenges. The earnings per share (EPS) for March 2023 registered at ₹10.09, which declined to ₹7.41 in March 2024 but recovered to ₹10.06 in March 2025. The company maintains a notable return on equity (ROE) of 18.8% and return on capital employed (ROCE) of 25.1%, indicating effective capital utilization despite variations in profitability. The interest coverage ratio (ICR) stood impressively at 128.35x, reflecting strong earnings relative to interest expenses and suggesting minimal financial strain. However, the cash conversion cycle (CCC) at 136 days indicates a relatively longer duration to convert investments into cash flow, which could present liquidity concerns if not managed effectively. Overall, while the company showcases strong profitability metrics, there are evident areas for enhancement in operational efficiency.
Balance Sheet Strength and Financial Ratios
Sumitomo Chemical India exhibits a solid balance sheet, with total assets amounting to ₹3,930 Cr as of March 2025, compared to total liabilities of ₹3,930 Cr, resulting in a debt-to-equity ratio of just 0.01. This indicates a conservative financial structure with minimal reliance on debt, as borrowings stood at only ₹45 Cr. The reserves have increased significantly to ₹2,397 Cr by March 2025, up from ₹1,881 Cr in March 2023. The company’s liquidity ratios reflect a strong position, with a current ratio of 3.13 and a quick ratio of 2.40, suggesting ample short-term liquidity to cover liabilities. The price-to-book value (P/BV) ratio of 9.61x indicates that the stock may be trading at a premium compared to its book value, which could imply strong market expectations for future growth. Additionally, the operating profit margin (OPM) of 20% for the most recent fiscal year aligns well within typical sector ranges, showcasing operational efficiency. The balance sheet strength, coupled with strong liquidity ratios, provides a solid foundation for future growth and strategic investments.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sumitomo Chemical India reflects a strong promoter commitment, with promoters holding 75% of the equity. Foreign institutional investors (FIIs) have increased their stake from 2.05% in September 2022 to 3.65% by March 2025, indicating growing confidence among international investors. Domestic institutional investors (DIIs) have also shown a positive trend, rising from 6.39% to 8.15% during the same period. However, public shareholding has decreased from 16.54% in September 2022 to 13.19% in March 2025, which may raise concerns about retail investor sentiment. The total number of shareholders has fluctuated, standing at 1,24,950 as of June 2025, down from a peak of 1,56,136 in June 2023. This shift may signal a consolidation phase among institutional investors, suggesting a potential shift in market dynamics. Overall, the strong promoter holding and increasing institutional interest reflect a solid foundation of investor confidence, though the decline in public shareholding warrants attention for future engagement strategies.
Outlook, Risks, and Final Insight
If margins sustain around current levels, Sumitomo Chemical India could leverage its strong market position to enhance profitability and operational efficiency. However, risks such as fluctuating commodity prices, regulatory challenges in the agrochemicals sector, and potential disruptions in supply chains could impact future performance. Additionally, the company’s ability to manage its cash conversion cycle effectively will be crucial in maintaining liquidity and operational flexibility. The recent decline in net profit and EPS in March 2024 indicates the need for strategic initiatives to bolster financial performance. If the company can navigate these challenges while capitalizing on its solid balance sheet and operational strengths, it may achieve sustained growth in a competitive landscape. The combination of strong promoter support and increasing institutional interest could provide the necessary backing for future strategic initiatives, positioning the company favorably for long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Sumitomo Chemical India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 7,337 Cr. | 1,701 | 2,243/1,502 | 17.0 | 441 | 0.35 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 1,016 Cr. | 301 | 391/165 | 19.4 | 117 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 55.2 Cr. | 106 | 148/55.2 | 10.1 | 34.1 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 3,169 Cr. | 244 | 392/234 | 111 | 53.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 785 Cr. | 332 | 670/244 | 11.5 | 320 | 0.90 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,349.65 Cr | 1,519.48 | 34.46 | 440.43 | 0.42% | 15.21% | 19.87% | 7.25 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 986 | 1,122 | 753 | 652 | 724 | 903 | 540 | 664 | 832 | 971 | 622 | 665 | 1,048 |
| Expenses | 798 | 843 | 632 | 571 | 643 | 715 | 474 | 526 | 670 | 729 | 521 | 548 | 828 |
| Operating Profit | 188 | 278 | 121 | 81 | 81 | 188 | 66 | 139 | 162 | 242 | 101 | 117 | 220 |
| OPM % | 19% | 25% | 16% | 12% | 11% | 21% | 12% | 21% | 19% | 25% | 16% | 18% | 21% |
| Other Income | 5 | 11 | 13 | 17 | 18 | 25 | 27 | 27 | 26 | 31 | 31 | 31 | 39 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 11 | 15 | 11 | 14 | 14 | 16 | 16 | 16 | 14 | 15 | 18 | 16 | 15 |
| Profit before tax | 180 | 272 | 121 | 82 | 83 | 196 | 76 | 149 | 173 | 257 | 113 | 132 | 242 |
| Tax % | 23% | 26% | 25% | 12% | 26% | 27% | 27% | 26% | 26% | 26% | 25% | 25% | 26% |
| Net Profit | 138 | 202 | 91 | 72 | 62 | 144 | 55 | 109 | 128 | 191 | 84 | 98 | 180 |
| EPS in Rs | 2.77 | 4.05 | 1.82 | 1.45 | 1.24 | 2.88 | 1.10 | 2.19 | 2.57 | 3.82 | 1.69 | 1.97 | 3.60 |
Last Updated: August 20, 2025, 3:00 am
Below is a detailed analysis of the quarterly data for Sumitomo Chemical India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,048.00 Cr.. The value appears strong and on an upward trend. It has increased from 665.00 Cr. (Mar 2025) to 1,048.00 Cr., marking an increase of 383.00 Cr..
- For Expenses, as of Jun 2025, the value is 828.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 548.00 Cr. (Mar 2025) to 828.00 Cr., marking an increase of 280.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 220.00 Cr.. The value appears strong and on an upward trend. It has increased from 117.00 Cr. (Mar 2025) to 220.00 Cr., marking an increase of 103.00 Cr..
- For OPM %, as of Jun 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 21.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 8.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 242.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 242.00 Cr., marking an increase of 110.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 180.00 Cr.. The value appears strong and on an upward trend. It has increased from 98.00 Cr. (Mar 2025) to 180.00 Cr., marking an increase of 82.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.60. The value appears strong and on an upward trend. It has increased from 1.97 (Mar 2025) to 3.60, marking an increase of 1.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 7:02 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 635 | 671 | 724 | 799 | 1,911 | 2,223 | 2,423 | 2,643 | 3,060 | 3,511 | 2,833 | 3,090 | 3,307 |
| Expenses | 587 | 614 | 635 | 698 | 1,691 | 1,932 | 2,088 | 2,155 | 2,458 | 2,843 | 2,358 | 2,467 | 2,626 |
| Operating Profit | 48 | 57 | 89 | 101 | 219 | 291 | 335 | 488 | 603 | 668 | 474 | 623 | 680 |
| OPM % | 8% | 8% | 12% | 13% | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% | 21% |
| Other Income | 3 | 8 | 26 | 10 | 31 | -0 | -20 | 19 | 36 | 45 | 96 | 119 | 132 |
| Interest | 2 | 1 | 1 | 1 | 5 | 5 | 7 | 7 | 8 | 6 | 5 | 6 | 5 |
| Depreciation | 6 | 6 | 7 | 7 | 24 | 28 | 41 | 47 | 45 | 52 | 61 | 63 | 64 |
| Profit before tax | 43 | 58 | 107 | 103 | 221 | 258 | 267 | 453 | 586 | 655 | 503 | 674 | 743 |
| Tax % | 23% | 40% | 40% | 40% | 34% | 35% | 23% | 24% | 26% | 23% | 27% | 26% | |
| Net Profit | 33 | 35 | 65 | 62 | 145 | 167 | 206 | 345 | 434 | 503 | 370 | 502 | 553 |
| EPS in Rs | 4.12 | 6.92 | 8.69 | 10.09 | 7.41 | 10.06 | 11.08 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 38% | 18% | 12% | 12% | 12% | 80% | 12% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.06% | 85.71% | -4.62% | 133.87% | 15.17% | 23.35% | 67.48% | 25.80% | 15.90% | -26.44% | 35.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | 79.65% | -90.33% | 138.49% | -118.70% | 8.18% | 44.12% | -41.68% | -9.90% | -42.34% | 62.12% |
Sumitomo Chemical India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 5% |
| 3 Years: | 0% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 17% |
| 3 Years: | 5% |
| TTM: | 27% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 6% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 21% |
| 3 Years: | 19% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 1:36 pm
Balance Sheet
Last Updated: July 25, 2025, 2:16 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 233 | 233 | 233 | 275 | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | -36 | -2 | 63 | 360 | 665 | 761 | 710 | 1,029 | 1,425 | 1,881 | 1,941 | 2,397 |
| Borrowings | 0 | 0 | 0 | 0 | 10 | 20 | 36 | 33 | 38 | 34 | 25 | 45 |
| Other Liabilities | 243 | 234 | 280 | 288 | 695 | 791 | 848 | 1,097 | 1,047 | 955 | 822 | 988 |
| Total Liabilities | 440 | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 |
| Fixed Assets | 47 | 51 | 52 | 53 | 267 | 279 | 319 | 309 | 390 | 430 | 489 | 482 |
| CWIP | 0 | 0 | 1 | 7 | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 28 |
| Investments | 0 | 0 | 0 | 277 | 2 | 1 | 87 | 291 | 357 | 239 | 425 | 601 |
| Other Assets | 393 | 415 | 523 | 585 | 1,367 | 1,558 | 1,676 | 2,043 | 2,227 | 2,628 | 2,351 | 2,819 |
| Total Assets | 440 | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 |
Below is a detailed analysis of the balance sheet data for Sumitomo Chemical India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 499.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 499.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,397.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,941.00 Cr. (Mar 2024) to 2,397.00 Cr., marking an increase of 456.00 Cr..
- For Borrowings, as of Mar 2025, the value is 45.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 25.00 Cr. (Mar 2024) to 45.00 Cr., marking an increase of 20.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 988.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 822.00 Cr. (Mar 2024) to 988.00 Cr., marking an increase of 166.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3,930.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,287.00 Cr. (Mar 2024) to 3,930.00 Cr., marking an increase of 643.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 482.00 Cr.. The value appears to be declining and may need further review. It has decreased from 489.00 Cr. (Mar 2024) to 482.00 Cr., marking a decrease of 7.00 Cr..
- For CWIP, as of Mar 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2024) to 28.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Mar 2025, the value is 601.00 Cr.. The value appears strong and on an upward trend. It has increased from 425.00 Cr. (Mar 2024) to 601.00 Cr., marking an increase of 176.00 Cr..
- For Other Assets, as of Mar 2025, the value is 2,819.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,351.00 Cr. (Mar 2024) to 2,819.00 Cr., marking an increase of 468.00 Cr..
- For Total Assets, as of Mar 2025, the value is 3,930.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,287.00 Cr. (Mar 2024) to 3,930.00 Cr., marking an increase of 643.00 Cr..
Notably, the Reserves (2,397.00 Cr.) exceed the Borrowings (45.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 48.00 | 57.00 | 89.00 | 101.00 | 209.00 | 271.00 | 299.00 | 455.00 | 565.00 | 634.00 | 449.00 | 578.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 83 | 92 | 101 | 105 | 110 | 128 | 117 | 101 | 98 | 91 | 90 |
| Inventory Days | 125 | 135 | 169 | 191 | 202 | 193 | 133 | 185 | 198 | 157 | 135 | 154 |
| Days Payable | 134 | 109 | 132 | 115 | 176 | 136 | 112 | 145 | 110 | 87 | 96 | 107 |
| Cash Conversion Cycle | 81 | 109 | 130 | 177 | 131 | 167 | 150 | 157 | 189 | 168 | 131 | 136 |
| Working Capital Days | 58 | 69 | 79 | 113 | 113 | 116 | 109 | 95 | 127 | 136 | 173 | 183 |
| ROCE % | 25% | 27% | 41% | 22% | 29% | 27% | 26% | 33% | 34% | 30% | 21% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| 360 ONE Focused Equity Fund | 3,623,637 | 2.38 | 146.41 | 3,623,637 | 2025-04-22 17:25:20 | 0% |
| Axis Midcap Fund | 2,222,646 | 0.37 | 89.81 | 2,222,646 | 2025-04-22 17:25:20 | 0% |
| HSBC Small Cap Fund - Regular Plan | 2,106,600 | 0.64 | 85.12 | 2,106,600 | 2025-04-22 17:25:20 | 0% |
| Axis Growth Opportunities Fund | 1,859,682 | 0.7 | 75.14 | 1,859,682 | 2025-04-22 17:25:20 | 0% |
| PGIM India Midcap Opportunities Fund | 1,578,298 | 0.63 | 63.77 | 1,578,298 | 2025-04-22 17:25:20 | 0% |
| ICICI Prudential MidCap Fund | 1,063,453 | 0.84 | 42.97 | 1,063,453 | 2025-04-22 17:25:20 | 0% |
| Tata Ethical Fund - Regular Plan | 797,200 | 1.47 | 32.21 | 797,200 | 2025-04-22 17:25:20 | 0% |
| Aditya Birla Sun Life MNC Fund - Div | 647,284 | 0.73 | 26.15 | 647,284 | 2025-04-22 17:25:20 | 0% |
| Aditya Birla Sun Life MNC Fund - Gr | 647,284 | 0.73 | 26.15 | 647,284 | 2025-04-22 17:25:20 | 0% |
| ICICI Prudential Manufacturing Fund | 508,258 | 0.9 | 20.54 | 508,258 | 2025-04-22 17:25:20 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.13 | 7.40 | 10.06 | 8.49 | 6.92 |
| Diluted EPS (Rs.) | 10.13 | 7.40 | 10.06 | 8.49 | 6.92 |
| Cash EPS (Rs.) | 11.47 | 8.65 | 11.10 | 9.38 | 7.85 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 58.12 | 48.97 | 47.72 | 38.61 | 30.88 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 58.12 | 48.97 | 47.72 | 38.61 | 30.88 |
| Revenue From Operations / Share (Rs.) | 63.08 | 56.98 | 70.34 | 61.40 | 52.99 |
| PBDIT / Share (Rs.) | 15.07 | 11.42 | 14.25 | 12.56 | 10.13 |
| PBIT / Share (Rs.) | 13.74 | 10.18 | 13.21 | 11.66 | 9.19 |
| PBT / Share (Rs.) | 13.63 | 10.08 | 13.11 | 11.53 | 9.08 |
| Net Profit / Share (Rs.) | 10.15 | 7.41 | 10.06 | 8.48 | 6.92 |
| NP After MI And SOA / Share (Rs.) | 10.13 | 7.40 | 10.06 | 8.48 | 6.92 |
| PBDIT Margin (%) | 23.88 | 20.05 | 20.26 | 20.45 | 19.10 |
| PBIT Margin (%) | 21.79 | 17.86 | 18.78 | 18.98 | 17.34 |
| PBT Margin (%) | 21.60 | 17.68 | 18.63 | 18.78 | 17.13 |
| Net Profit Margin (%) | 16.08 | 13.00 | 14.30 | 13.82 | 13.05 |
| NP After MI And SOA Margin (%) | 16.05 | 12.99 | 14.30 | 13.82 | 13.05 |
| Return on Networth / Equity (%) | 17.42 | 15.13 | 21.08 | 21.97 | 22.40 |
| Return on Capital Employeed (%) | 22.87 | 20.22 | 27.07 | 29.26 | 28.84 |
| Return On Assets (%) | 12.75 | 11.15 | 14.90 | 14.07 | 12.93 |
| Asset Turnover Ratio (%) | 0.86 | 0.85 | 1.10 | 1.08 | 1.11 |
| Current Ratio (X) | 3.13 | 3.34 | 2.99 | 2.47 | 2.14 |
| Quick Ratio (X) | 2.40 | 2.58 | 2.03 | 1.55 | 1.44 |
| Inventory Turnover Ratio (X) | 2.42 | 1.88 | 2.03 | 2.18 | 2.33 |
| Dividend Payout Ratio (NP) (%) | 8.88 | 83.74 | 9.93 | 9.42 | 7.95 |
| Dividend Payout Ratio (CP) (%) | 7.85 | 71.68 | 9.00 | 8.52 | 7.00 |
| Earning Retention Ratio (%) | 91.12 | 16.26 | 90.07 | 90.58 | 92.05 |
| Cash Earning Retention Ratio (%) | 92.15 | 28.32 | 91.00 | 91.48 | 93.00 |
| Interest Coverage Ratio (X) | 128.35 | 111.66 | 131.90 | 101.62 | 90.99 |
| Interest Coverage Ratio (Post Tax) (X) | 87.42 | 73.40 | 94.11 | 69.68 | 63.18 |
| Enterprise Value (Cr.) | 27850.93 | 17160.49 | 20923.34 | 22359.99 | 14273.20 |
| EV / Net Operating Revenue (X) | 8.85 | 6.03 | 5.96 | 7.30 | 5.40 |
| EV / EBITDA (X) | 37.03 | 30.09 | 29.41 | 35.68 | 28.24 |
| MarketCap / Net Operating Revenue (X) | 8.86 | 6.10 | 6.05 | 7.32 | 5.49 |
| Retention Ratios (%) | 91.11 | 16.25 | 90.06 | 90.57 | 92.04 |
| Price / BV (X) | 9.61 | 7.10 | 8.91 | 11.64 | 9.42 |
| Price / Net Operating Revenue (X) | 8.86 | 6.10 | 6.05 | 7.32 | 5.49 |
| EarningsYield | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 |
After reviewing the key financial ratios for Sumitomo Chemical India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 7.40 (Mar 24) to 10.13, marking an increase of 2.73.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 7.40 (Mar 24) to 10.13, marking an increase of 2.73.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.47. This value is within the healthy range. It has increased from 8.65 (Mar 24) to 11.47, marking an increase of 2.82.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 58.12. It has increased from 48.97 (Mar 24) to 58.12, marking an increase of 9.15.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 58.12. It has increased from 48.97 (Mar 24) to 58.12, marking an increase of 9.15.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 63.08. It has increased from 56.98 (Mar 24) to 63.08, marking an increase of 6.10.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.07. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 15.07, marking an increase of 3.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.74. This value is within the healthy range. It has increased from 10.18 (Mar 24) to 13.74, marking an increase of 3.56.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.63. This value is within the healthy range. It has increased from 10.08 (Mar 24) to 13.63, marking an increase of 3.55.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.15. This value is within the healthy range. It has increased from 7.41 (Mar 24) to 10.15, marking an increase of 2.74.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 7.40 (Mar 24) to 10.13, marking an increase of 2.73.
- For PBDIT Margin (%), as of Mar 25, the value is 23.88. This value is within the healthy range. It has increased from 20.05 (Mar 24) to 23.88, marking an increase of 3.83.
- For PBIT Margin (%), as of Mar 25, the value is 21.79. This value exceeds the healthy maximum of 20. It has increased from 17.86 (Mar 24) to 21.79, marking an increase of 3.93.
- For PBT Margin (%), as of Mar 25, the value is 21.60. This value is within the healthy range. It has increased from 17.68 (Mar 24) to 21.60, marking an increase of 3.92.
- For Net Profit Margin (%), as of Mar 25, the value is 16.08. This value exceeds the healthy maximum of 10. It has increased from 13.00 (Mar 24) to 16.08, marking an increase of 3.08.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.05. This value is within the healthy range. It has increased from 12.99 (Mar 24) to 16.05, marking an increase of 3.06.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.42. This value is within the healthy range. It has increased from 15.13 (Mar 24) to 17.42, marking an increase of 2.29.
- For Return on Capital Employeed (%), as of Mar 25, the value is 22.87. This value is within the healthy range. It has increased from 20.22 (Mar 24) to 22.87, marking an increase of 2.65.
- For Return On Assets (%), as of Mar 25, the value is 12.75. This value is within the healthy range. It has increased from 11.15 (Mar 24) to 12.75, marking an increase of 1.60.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.86. It has increased from 0.85 (Mar 24) to 0.86, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 3.13. This value exceeds the healthy maximum of 3. It has decreased from 3.34 (Mar 24) to 3.13, marking a decrease of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 2.40. This value exceeds the healthy maximum of 2. It has decreased from 2.58 (Mar 24) to 2.40, marking a decrease of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.42. This value is below the healthy minimum of 4. It has increased from 1.88 (Mar 24) to 2.42, marking an increase of 0.54.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.88. This value is below the healthy minimum of 20. It has decreased from 83.74 (Mar 24) to 8.88, marking a decrease of 74.86.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 7.85. This value is below the healthy minimum of 20. It has decreased from 71.68 (Mar 24) to 7.85, marking a decrease of 63.83.
- For Earning Retention Ratio (%), as of Mar 25, the value is 91.12. This value exceeds the healthy maximum of 70. It has increased from 16.26 (Mar 24) to 91.12, marking an increase of 74.86.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 92.15. This value exceeds the healthy maximum of 70. It has increased from 28.32 (Mar 24) to 92.15, marking an increase of 63.83.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 128.35. This value is within the healthy range. It has increased from 111.66 (Mar 24) to 128.35, marking an increase of 16.69.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 87.42. This value is within the healthy range. It has increased from 73.40 (Mar 24) to 87.42, marking an increase of 14.02.
- For Enterprise Value (Cr.), as of Mar 25, the value is 27,850.93. It has increased from 17,160.49 (Mar 24) to 27,850.93, marking an increase of 10,690.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.85. This value exceeds the healthy maximum of 3. It has increased from 6.03 (Mar 24) to 8.85, marking an increase of 2.82.
- For EV / EBITDA (X), as of Mar 25, the value is 37.03. This value exceeds the healthy maximum of 15. It has increased from 30.09 (Mar 24) to 37.03, marking an increase of 6.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 6.10 (Mar 24) to 8.86, marking an increase of 2.76.
- For Retention Ratios (%), as of Mar 25, the value is 91.11. This value exceeds the healthy maximum of 70. It has increased from 16.25 (Mar 24) to 91.11, marking an increase of 74.86.
- For Price / BV (X), as of Mar 25, the value is 9.61. This value exceeds the healthy maximum of 3. It has increased from 7.10 (Mar 24) to 9.61, marking an increase of 2.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 6.10 (Mar 24) to 8.86, marking an increase of 2.76.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sumitomo Chemical India Ltd:
- Net Profit Margin: 16.08%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 22.87% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.42% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 87.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 47.5 (Industry average Stock P/E: 34.46)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.08%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Bldg. No. 1, Ground Floor, Shant Manor Co-op Housing Society Ltd., Mumbai Maharashtra 400101 | investor.relations@sumichem.co.in http://www.sumichem.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mukul G Asher | Chairman |
| Mr. Chetan Shah | Managing Director |
| Dr. Suresh Ramachandran | Deputy Managing Director |
| Mr. Sushil Marfatia | Executive Director |
| Mr. N Sivaraman | Independent Director |
| Mrs. Preeti Mehta | Independent Director |
| Mr. Ninad D Gupte | Non Exe.Non Ind.Director |
| Mr. Masanori Uzawa | Non Exe.Non Ind.Director |
| Mr. Tadashi Katayama | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Sumitomo Chemical India Ltd?
Sumitomo Chemical India Ltd's intrinsic value (as of 18 October 2025) is 415.31 which is 21.04% lower the current market price of 526.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 26,275 Cr. market cap, FY2025-2026 high/low of 665/446, reserves of ₹2,397 Cr, and liabilities of 3,930 Cr.
What is the Market Cap of Sumitomo Chemical India Ltd?
The Market Cap of Sumitomo Chemical India Ltd is 26,275 Cr..
What is the current Stock Price of Sumitomo Chemical India Ltd as on 18 October 2025?
The current stock price of Sumitomo Chemical India Ltd as on 18 October 2025 is 526.
What is the High / Low of Sumitomo Chemical India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sumitomo Chemical India Ltd stocks is 665/446.
What is the Stock P/E of Sumitomo Chemical India Ltd?
The Stock P/E of Sumitomo Chemical India Ltd is 47.5.
What is the Book Value of Sumitomo Chemical India Ltd?
The Book Value of Sumitomo Chemical India Ltd is 58.0.
What is the Dividend Yield of Sumitomo Chemical India Ltd?
The Dividend Yield of Sumitomo Chemical India Ltd is 0.23 %.
What is the ROCE of Sumitomo Chemical India Ltd?
The ROCE of Sumitomo Chemical India Ltd is 25.1 %.
What is the ROE of Sumitomo Chemical India Ltd?
The ROE of Sumitomo Chemical India Ltd is 18.8 %.
What is the Face Value of Sumitomo Chemical India Ltd?
The Face Value of Sumitomo Chemical India Ltd is 10.0.